Project Grant R01DK143288
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded New York University School of Medicine $847,495 on February 19, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to build expert consensus on stratified kidney allocation design, estimate the policy impact of stratified allocation systems to assist policymakers, and investigate patient, care partner, and provider attitudes and perceptions regarding shared decision-making...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded New York University $872,273 on August 20, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to identify modifiable process delays in deceased donor kidney allocation through process mining analysis. The project applies process mining methodology to discover actual kidney placement workflows from data logs at multiple organ procurement organizations (OPOs). The research...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded New York University $1.65 million on September 15, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to evaluate and design a new kidney allocation policy permitting ABO-compatible transplants. The research addresses a persistent gap in the current U.S. kidney allocation system: high-sensitized patients with blood types B and O remain underserved despite the 2014 policy...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded New York University School of Medicine $877,742 on September 2, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to evaluate the effect of a state-wide centralized patient coaching program about live donor kidney transplantation. The award funds the Live Donor Champion (LDC) program, which educates end-stage kidney disease patients, their caregivers, and social...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded New York University School of Medicine $2,557,884 on September 10, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct a detailed analysis of long-term health outcomes in living kidney donors using real-world electronic health records. The recipient will analyze the COSMOS dataset, which encompasses electronic health records from over 245 million individuals...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded New York University (doing business as New York University School of Medicine) $1.674 million on September 24, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop an empirically-based, optimal prehabilitation program for kidney transplant candidates on hemodialysis. The research addresses a significant clinical need: of more than 140,000 people waiting for kidney...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Washington University $766,951 on April 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop and validate imaging biomarkers for assessing high-risk deceased donor kidneys slated for transplantation. The project addresses kidney shortage by improving the accuracy of kidney quality assessment, reducing the approximately 2,500 procured kidneys discarded...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Research Foundation for the State University of New York $327,450 on August 20, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct research on reducing geographic disparity in access to deceased donor kidney transplantation. The recipient will employ advanced statistical methods, artificial intelligence, and operations research to understand complex dynamics...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded New York University $1.693 million on September 15, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop individualized immunosuppression regimens for kidney transplant recipients using machine learning and electronic health record data. The project addresses a clinical gap in immunosuppressive therapy optimization. Over 250,000 kidney transplant recipients depend...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Tennessee $639,022 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847, Assistance Type: Project Grant). The award funds a one-year research study designed to promote HIV-to-HIV kidney transplantation as standard-of-care clinical practice in the new regulatory environment following November 2024 modifications to transplant eligibility...
The National Institute of Diabetes and Digestive and Kidney Diseases awarded New York University $847,498 on August 20, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop and validate strategies for integrating deceased-donor-initiated kidney paired donation (DD-KPD) chains into the U.S. kidney allocation system. The project addresses the kidney shortage and stagnation in living donation by redirecting a small percentage of deceased donors to initiate KPD chains, with the goal of adding up to 1,488 living donor transplants annually while protecting access for blood types at risk and reducing transplant wait times for highly HLA-sensitized candidates. Specific Aim 1 develops the Unified Kidney Donor Profile Index (UKDPI), a donor-only risk metric that places living and deceased donors on a common, calibrated scale for transparent quality comparisons. Using National Registry data spanning 2015–2025 on over 159,000 recipients and over 160,000 donors, the work will estimate standardized five-year graft-failure risk, benchmark performance against existing metrics (KDPI/LKDPI), and characterize deceased donors suitable to initiate DD-KPD chains. Specific Aim 2 builds the first joint simulator of deceased donor allocation and KPD and designs a DD-KPD policy that maintains blood-type fairness, using stochastic optimization to guarantee that kidneys returned from DD-KPD chains offset any diversion of O and B organs. Performance takes place in New York, New York. The period of performance runs through April 30, 2031.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $847.5k | 8/20/26 |